Application of PBPK modelling for prediction of tacrolimus exposure in CYP3A combined genotype groups (CYP3A4*22 and/or CYP3A5*3) and a renal transplant population Poster Application of PBPK modelling for prediction of tacrolimus exposure in CYP3A combined genotype groups (CYP3A4*22 and/or CYP3A5*3) and a renal transplant population CertaraSeptember 2, 2019
Assessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling Poster Assessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling CertaraSeptember 2, 2019
In Vitro to In Vivo Extrapolation of Valproic Acid Hepatotoxicity: a Biokinetic and Physiologically Based Toxicokinetic Informed Approach Poster In Vitro to In Vivo Extrapolation of Valproic Acid Hepatotoxicity: a Biokinetic and Physiologically Based Toxicokinetic Informed Approach CertaraSeptember 2, 2019
Iterative Development of a Physiologically Based Pharmacokinetic Model for Valproic Acid and Reverse Translation of In Vitro Toxicity Data Poster Iterative Development of a Physiologically Based Pharmacokinetic Model for Valproic Acid and Reverse Translation of In Vitro Toxicity Data CertaraSeptember 2, 2019
Iterative Development and Performance Verification of In Vitro Biokinetic Models Poster Iterative Development and Performance Verification of In Vitro Biokinetic Models CertaraSeptember 2, 2019
Lysosomes- falling into a trap of our own making? Poster Lysosomes- falling into a trap of our own making? CertaraSeptember 2, 2019
Physiologically-Based Pharmacokinetic Modelling of Cyclosporine A in Rat Poster Physiologically-Based Pharmacokinetic Modelling of Cyclosporine A in Rat CertaraSeptember 2, 2019
USE OF A PBPK APPROACH TO ASSESS THE RISK OF DRUG INTERACTIONS IN DIABETIC PATIENTS ON POLYPHARMACY TREATMENT REGIMENS Poster USE OF A PBPK APPROACH TO ASSESS THE RISK OF DRUG INTERACTIONS IN DIABETIC PATIENTS ON POLYPHARMACY TREATMENT REGIMENS CertaraSeptember 2, 2019
APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTION OF CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDIs) INVOLVING ETHINYLESTRADIOL (EE) Poster APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTION OF CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDIs) INVOLVING ETHINYLESTRADIOL (EE) CertaraSeptember 2, 2019
Sulfasalazine a BCRP probe substrate: development of a physiologically based pharmacokinetic (PBPK) model Poster Sulfasalazine a BCRP probe substrate: development of a physiologically based pharmacokinetic (PBPK) model CertaraAugust 30, 2019
